There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Celcuity (CELC – Research Report) and 89bio (ETNB – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
In a report released today, Geoff Meacham from Bank of America Securities maintained a Buy rating on Eli Lilly & Co. The company’s shares closed last Wednesday at $787.02, close to its 52-week high of $800.78.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $881.00, representing a 15.3% upside. In a report issued on May 1, Barclays also maintained a Buy rating on the stock with a $913.00 price target.
See today’s best-performing stocks on TipRanks >>
Celcuity (CELC)
In a report released today, Chase Knickerbocker from Craig-Hallum reiterated a Buy rating on Celcuity, with a price target of $27.00. The company’s shares closed last Wednesday at $17.23.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
Celcuity has an analyst consensus of Strong Buy, with a price target consensus of $29.50, implying a 74.7% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $27.00 price target.
89bio (ETNB)
In a report released today, Alexandria Hammond from Bank of America Securities maintained a Buy rating on 89bio. The company’s shares closed last Wednesday at $9.20, close to its 52-week low of $6.58.
According to TipRanks.com, Hammond is ranked #5804 out of 8856 analysts.
Currently, the analyst consensus on 89bio is a Moderate Buy with an average price target of $28.00, a 205.0% upside from current levels. In a report issued on May 10, H.C. Wainwright also maintained a Buy rating on the stock with a $29.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- Eli Lilly announces retirement of Chief Ethics and Compliance Officer Weems
- New Analyst Adjustments Prove Little Help to Eli Lilly (NYSE:LLY)
- Eli Lilly price target raised to $840 from $770 at Argus
- Cipla Wants to Partner with Eli Lilly (NYSE:LLY) in India
- Rani Therapeutics price target raised to $14 from $7 at BTIG
